SCHEMBL15076518

SCHEMBL15076518

O=C(Nc1ccccc1Cl)c1cc(S(=O)(=O)N2CCCCC2)ccc1F

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.77
HTT P42858 2/20 0.77
TSHR P16473 1/20 0.77
MAPT P10636 6/20 0.77
KDM4E B2RXH2 3/20 0.77
GAA P10253 1/20 0.77
UBE2N P61088 1/20 0.74
KMT2A Q03164 3/20 0.68
NPSR1 Q6W5P4 1/20 0.68
TP53 P04637 7/20 0.68
LMNA P02545 3/20 0.68
MEN1 O00255 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.66
POLB P06746 1/20 0.64
HPGD P15428 1/20 0.64
NPY1R P25929 1/20 0.64
NPY2R P49146 1/20 0.64
PAX8 Q06710 1/20 0.64
RCE1 Q9Y256 1/20 0.64
CYP3A4 P08684 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15076665 0.86 TP53 (0.76) ALDH1A1HTTTSHRMAPTKDM4E
SCHEMBL17479171 0.85 MAPT (0.80) ALDH1A1HTTTSHRMAPTKDM4E
SCHEMBL15276778 0.84 MAPT (0.83) ALDH1A1HTTMAPTKDM4EGAA
SCHEMBL15076666 0.83 TP53 (0.77) TSHRMAPTKDM4EGAAUBE2N
SCHEMBL15076522 0.82 TP53 (0.75) ALDH1A1HTTTSHRMAPTKDM4E
SCHEMBL17479136 0.81 SMN1; SMN2 (0.98) ALDH1A1HTTTSHRMAPTKDM4E
SCHEMBL15847800 0.81 TP53 (0.83) ALDH1A1TSHRMAPTKDM4EGAA
SCHEMBL1001462 0.81 TP53 (0.73) ALDH1A1HTTTSHRMAPTGAA
SCHEMBL15076514 0.81 TP53 (0.78) ALDH1A1HTTTSHRMAPTKDM4E
SCHEMBL14484815 0.81 TP53 (0.83) ALDH1A1TSHRMAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10196376-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2019-02-05 US disclosed
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC 2017-11-23 US disclosed
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC 2017-11-23 US disclosed
US-9751857-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-09-05 US disclosed
US-9751857-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-09-05 US disclosed
EP-2794565-B1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS INC (US) 2017-07-26 EP disclosed
US-9676747-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-06-13 US disclosed
US-9676747-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-06-13 US disclosed
US-20150259324-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2015-09-17 US disclosed
US-20150259324-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2015-09-17 US disclosed
US-20150152073-A1 Hepatitis B Antiviral Agents NOVIRA THERAPEUTICS, INC. 2015-06-04 US disclosed
US-20150152073-A1 Hepatitis B Antiviral Agents NOVIRA THERAPEUTICS, INC. 2015-06-04 US disclosed
US-20140179665-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2014-06-26 US disclosed
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2014-06-26 US disclosed
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2014-06-26 US disclosed
US-8629274-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2014-01-14 US disclosed
US-8629274-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2014-01-14 US disclosed
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-09-26 US disclosed
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-09-26 US disclosed
WO-2013096744-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152073-A1 Hepatitis B Antiviral Agents HAVCR2, EIF2AK2, IRF3 ALDH1A1 1564/4885HTT 3427/4885TSHR 4028/4885
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 ALDH1A1 1564/4885HTT 3427/4885TSHR 4028/4885
US-10196376-B2 Hepatitis B antiviral agents HAVCR2, EIF2AK2, IRF3 ALDH1A1 1564/4885HTT 3427/4885TSHR 4028/4885
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 ALDH1A1 1564/4885HTT 3427/4885TSHR 4028/4885
US-20140179665-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 ALDH1A1 1564/4885HTT 3427/4885TSHR 4028/4885
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 ALDH1A1 1564/4885HTT 3427/4885TSHR 4028/4885
US-20150259324-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 ALDH1A1 1564/4885HTT 3427/4885TSHR 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.